AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03319823
Drug: Thiazide Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure \<160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.~If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment
Trial: NCT03319823
Drug: Intensified Thiazide Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure \>120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure \>120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is \<120.
Trial: NCT03319823
Drug: Combination Medication Treatment Group
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg~* Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily~* After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring~  * If sleep systolic blood pressure is \< 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility~ * If sleep systolic blood pressure is \> 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy.
Trial: NCT02449161
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01959841
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once daily or 400 mg once daily
Trial: NCT00620724
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo three times daily
Trial: NCT04340544
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00185250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
Trial: NCT00185250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
Trial: NCT00508690
Drug: kanamycin/metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
Trial: NCT03732508
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil intravenous infusion will be administered during the first day of treatment.
Trial: NCT02312297
Drug: Minocycline hydrochloride
RxNorm normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: extended release tablets 135 mg
Trial: NCT00598897
Drug: clarithromycin, rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
Trial: NCT04156035
Drug: Placebo Pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine Placebo
Trial: NCT04156035
Drug: Placebo Infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine Placebo
Trial: NCT00001870
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03128242
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration of placebo (24IU)
Trial: NCT02915042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline placebo
Trial: NCT02038335
Drug: MPA/E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate and estradiol cypionate
Trial: NCT01905878
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00291187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00400556
Drug: ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02645461
Drug: endocannabinoid palmitoylethanolamide (PEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
Trial: NCT04445688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration before bed
Trial: NCT00971230
Drug: FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: emtricitabine/tenofovir disoproxil fumarate
Trial: NCT00971230
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00636441
Drug: Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
Trial: NCT00006204
Drug: fluoxetine (Prozac)
RxNorm normalized name: fluoxetine Oral Capsule [Prozac]
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06031376
Drug: Trifluridine/Tipiracil
RxNorm normalized name: TRIFLURIDINE/TIPIRACIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-102 35 mg/m²orally twice a day on days 1-5 and 8-12, every 28 days
Trial: NCT03325959
Drug: Cymbalta / Lyrica treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
Trial: NCT01719536
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
Trial: NCT01669772
Drug: DA-9701 and placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
Trial: NCT01669772
Drug: Placebo and DA-9701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
Trial: NCT01959139
Drug: PEGPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ug/kg on Day 1, IV over 15 minutes
Trial: NCT01959139
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2, on Day 2, IV over 2 hours
Trial: NCT02422485
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
Trial: NCT02709811
Drug: Electrochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005773
Drug: Inhaled Nitric Oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had \<=20 mm Hg increase in PaO2 (less than full response).
Trial: NCT00005773
Drug: Standard iNO therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI \>=25).
Trial: NCT03158948
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01953809
Drug: GSK1322322
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
Trial: NCT01953809
Drug: EE/NE
RxNorm normalized name: EE/NETHDRONE (EQV-FEMHRT 1/5) TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
Trial: NCT01953809
Drug: GSK1322322 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
Trial: NCT01953809
Drug: EE/NE Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
Trial: NCT00328367
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01584739
Drug: AZD8683
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
Trial: NCT01584739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
Trial: NCT01577628
Drug: Lipikar Balm AP
RxNorm normalized name: La Roche-Posay Lipikar Balm AP+ Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of Lipikar Balm AP starting at birth
Trial: NCT00639366
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00208897
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03250832
Drug: TSR-033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSR-033 is a humanized monoclonal antibody immunoglobulin (Ig) G4.
Trial: NCT03250832
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and oxaliplatin (OX) which acts as systemic cytotoxic agent.
Trial: NCT03250832
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI is combination of folinic acid (FOL)/leucovorin, 5-fluorouracil and irinotecan (IRI) which acts as systemic cytotoxic agent.
Trial: NCT00020501
Drug: FOLFIRI regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00020501
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00020501
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01761019
Drug: Taclonex Topical Suspension
RxNorm normalized name: Taclonex Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical medication for psoriasis
Trial: NCT03168178
Drug: Standard Antibiotic Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to this intervention will receive standard antibiotic treatment.~The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
Trial: NCT00633529
Drug: IMO-2055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
Trial: NCT01561222
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one pill per day
Trial: NCT01689220
Drug: SP-02L (darinaparsin for injection)
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Trial: NCT01689220
Drug: SP-02L (darinaparsin for injection)
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
Trial: NCT02082405
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00090298
Drug: MK0653A, ezetimibe (+) simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00090298
Drug: Comparator: Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01843868
Drug: Standard anti-emetics in conjunction with R-CHOP
RxNorm normalized name: INVESTIGATIONAL ANTI-NAUSEA AND ANTI-EMETIC DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03193788
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
Trial: NCT01019980
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium
Trial: NCT01019980
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen
Trial: NCT01353456
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same volume as dexmedetomidine given
Trial: NCT01454986
Drug: ALXN1007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, IV
Trial: NCT00728091
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT00829127
Drug: AZD8075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
Trial: NCT00829127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT03137017
Drug: Norco 5Mg-325Mg Tablet
RxNorm normalized name: Norco 5mg-325mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose in one of the four cross-over trial periods.
Trial: NCT01313182
Drug: mupirocin calcium ointment, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.
Trial: NCT04628884
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose used to calculated the protamine dose
Trial: NCT04628884
Drug: Dosing according residual heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this group the heparin doses will be simulated using a pharmacokinetic model to estimated the residual heparin amount at the end of the surgery, the protamine dose will be calculated using the residual heparin
Trial: NCT00285077
Drug: SR57667B
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01263470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
Trial: NCT01134575
Drug: CMC-544 (Inotuzumab Ozogamycin)
RxNorm normalized name: CMC-583
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First patients \> 16 years and \< 16 years receive CMC-544 at a dose of 1.3 mg/m\^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m\^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m\^2 IV over 1 hour every 4 week cycle.~Part 2 CMC-544 (Inotuzumab Ozogamycin) 0.8 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 1, 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 8, and 0.5 mg/m\^2 IV over 1 hour (+ 15 minutes) on Day 15. Weekly doses can be given at + 1 day. Course may be repeated every 3 weeks. Rituximab will be given on Day 1 and CMC-544 on Day 2 of the first dose; with subsequent weekly doses, both will be given weekly, rituximab preceding CMC-544. The weekly dose of rituximab will be 375 mg/m2.
Trial: NCT04312568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation for 8 groups: 12.5mg one dose, 25mg one dose, 50mg one dose, 100mg one dose, 200mg one dose, 300mg one dose, 400mg one dose, 500mg one dose
Trial: NCT01766180
Drug: Fruitflow-II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day for 3 months, orally
Trial: NCT01766180
Drug: resVida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day for 3 months, orally
Trial: NCT03015831
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet will be given to open heart surgery patients according to randomization
Trial: NCT00941031
Drug: AIN457
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00941031
Drug: AIN457A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5
Trial: NCT00941031
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9
Trial: NCT01178762
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
Trial: NCT02377362
Drug: GLWL-01, Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally, in 2 out of 3 periods
Trial: NCT02377362
Drug: Placebo, Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally in 1 out of 3 periods
Trial: NCT02377362
Drug: GLWL-01, Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
Trial: NCT02377362
Drug: Placebo, Part B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Trial: NCT02377362
Drug: GLWL-01, Part C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
Trial: NCT00094809
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
Trial: NCT04164524
Drug: Gentamycin
RxNorm normalized name: Gentamicin Sulfate 3 MG/1 ML Ophthalmic Solution [GENTAMYCIN]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamycin 160 mg spray applied over the mesh
Trial: NCT00390403
Drug: R-(-)-gossypol acetic acid
RxNorm normalized name: citronellol acetate, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04593836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Trial: NCT01873807
Drug: IDA
RxNorm normalized name: Efidac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin: 15mg/m2/d: -8-\>-6d
Trial: NCT01873807
Drug: CTX
RxNorm normalized name: CTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CY:60mg/kg/d, -3d, -2d
Trial: NCT02180087
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00317655
Drug: Glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00317655
Drug: Ginger-ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000433
Drug: Anti-Tumor Necrosis Factor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00933868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
Trial: NCT01253499
Drug: TRx0037
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.